Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cluster of differentiation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Cluster of differentiation. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-000692-21 Sponsor Protocol Number: 213569 Start Date*: 2020-12-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 2b, open-label, multi-center, extension study to evaluate the safety and immunogenicity of a revaccination dose of the RSVPreF3 older adults (OA) investigational vaccine administered intram...
    Medical condition: Healthy volunteers (Active immunisation for the prevention of disease caused by RSV in adults aged 60 years or above)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002916-34 Sponsor Protocol Number: ITCC-054/AAML1921 Start Date*: 2016-06-13
    Sponsor Name:Erasmus MC
    Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009700 CML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000754-38 Sponsor Protocol Number: TMC114FD2HTX3001 Start Date*: 2015-08-19
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combinatio...
    Medical condition: Human Immunodeficiency Virus Type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004223-36 Sponsor Protocol Number: RI-01-006 Start Date*: 2019-09-23
    Sponsor Name:Dr. Reddy’s Laboratories S.A.
    Full Title: A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously ...
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016910 Follicle centre lymphoma, follicular grade I, II, III stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Ongoing) CZ (Completed) BG (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003655-37 Sponsor Protocol Number: 19764 Start Date*: 2019-09-23
    Sponsor Name:Bayer Consumer Care AG
    Full Title: Post-marketing investigation (PMI) to assess safety and efficacy of Jivi® (BAY 94-9027) treatment in patients with hemophilia A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003597-10 Sponsor Protocol Number: MK-8591A-028 Start Date*: 2020-07-15
    Sponsor Name:MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >=12 to <18 Years ...
    Medical condition: HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001928-17 Sponsor Protocol Number: GCT1046-04 Start Date*: 2021-08-13
    Sponsor Name:Genmab A/S
    Full Title: A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer...
    Medical condition: Malignant Solid Tumors - Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004606-10 Sponsor Protocol Number: 8VWF07 Start Date*: 2014-08-06
    Sponsor Name:BIO PRODUCTS LABORATORY LIMITED (BPL)
    Full Title: Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate® Treatment in Subjects with Severe Haemophilia A.
    Medical condition: Severe Haemophilia A
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007458-37 Sponsor Protocol Number: 973 Start Date*: 2009-12-22
    Sponsor Name:Biotest AG
    Full Title: A randomized, placebo-controlled, double-blind, multicentre, multiple dose, cohort study with escalating doses to evaluate the safety and efficacy of the humanized monoclonal antibody (mab) BT061 a...
    Medical condition: patients with moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    12.0 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-002456-24 Sponsor Protocol Number: 3082B2-4418 Start Date*: 2015-04-10
    Sponsor Name:Wyeth Research
    Full Title: A Post Authorization Safety Surveillance Study of Xyntha in Usual Care Settings
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060612 Hemophilia A LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004106-15 Sponsor Protocol Number: 3082B2-3316 Start Date*: 2015-04-03
    Sponsor Name:Wyeth Pharmaceutical Co., Ltd
    Full Title: An Evaluation of the Safety and Efficacy of On-Demand Treatment with Xyntha (B-Domain Deleted Recombinant Factor VIII, Albumin Free) in Chinese Subjects with Hemophilia A
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10018937 Haemophilia A LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000590-23 Sponsor Protocol Number: MK-8591A-020 Start Date*: 2020-03-31
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatm...
    Medical condition: HIV-1 infection and naïve to antiretroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004735-12 Sponsor Protocol Number: 20130286 Start Date*: 2017-04-06
    Sponsor Name:Amgen Inc
    Full Title: A Double Blind, Randomized, Placebo Controlled, Multicenter Study toEvaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or ...
    Medical condition: HIV and hyperlipidemia or mixed dyslipidemia.
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.1 100000004861 10020667 Hyperlipidemia LLT
    20.0 100000004848 10020180 HIV positive LLT
    20.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) GB (Completed) BE (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005046-23 Sponsor Protocol Number: POL 2 Start Date*: 2009-03-23
    Sponsor Name:Polyphor AG
    Full Title: A Phase IIa, Proof of Concept Study to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients with Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2014-004156-65 Sponsor Protocol Number: 3090A1-3305 Start Date*: 2015-04-06
    Sponsor Name:Wyeth Pharmaceutical Co, Ltd.
    Full Title: An Evaluation of the Safety and Efficacy of On-Demand Treatment with BeneFIX (Nonacog Alfa, Recombinant Factor IX) in Chinese Subjects with Hemophilia B
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000341-12 Sponsor Protocol Number: V114-030 Start Date*: 2019-11-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight...
    Medical condition: prevention of pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-004149-11 Sponsor Protocol Number: TAK-761-4009 Start Date*: 2023-07-27
    Sponsor Name:Takeda Biopharmaceuticals India Pvt. Ltd.
    Full Title: Phase 4, Multicenter, Prospective, Interventional, Post-Marketing Study in Hemophilia A Patients in India Receiving ADVATE as On-Demand or Prophylaxis Under Standard Clinical Practice
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005787-22 Sponsor Protocol Number: EP395-003 Start Date*: 2022-07-21
    Sponsor Name:EpiEndo Pharmaceuticals
    Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of EP395 in patients with chronic obstructive pulmonary disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003014-28 Sponsor Protocol Number: FARM12JCXN Start Date*: 2017-10-30
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: MULTICENTER RANDOMIZED STUDY ON THE EFFICACY OF IMMUNOSUPPRESSION IN PATIENTS WITH VIRUS-NEGATIVE INFLAMMATORY CARDIOMYOPATHY
    Medical condition: virus negative inflammatory cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006191-16 Sponsor Protocol Number: BAY94-9027/21924 Start Date*: 2024-10-29
    Sponsor Name:Bayer HealthCare Pharmaceuticals Inc.
    Full Title: A multicenter, prospective, open-label, clinical study to assess the effect of using a new risk score approach to select the most appropriate prophylaxis regimen for reaching a favorable outcome, w...
    Medical condition: Hemophilia A Prophylaxis of bleeding
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060613 Hemophilia A (Factor VIII) LLT
    20.0 10042613 - Surgical and medical procedures 10071818 Bleeding prophylaxis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:30:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA